Angiotech Pharmaceuticals News

Financial and Strategic Analysis Review Summary The "Angiotech Pharmaceuticals, Inc.

Angiotech Pharmaceuticals, Inc. - Medical Equipment - Deals and Alliances Profile - new report released 2009-11-16 06:25:23 - Angiotech Pharmaceuticals, Inc.

Angiotech Pharmaceuticals, Inc. posts loss of $7.8 million or nine cents per share in third quarter, down from $622.4 million or $7.31 a share in third quarter of 2008 when the company wrote down the value of its goodwill assets by $612.9 million.

Angiotech Pharmaceuticals, Inc. narrowed its losses in the third quarter as the medical-device company recovered from the impact of a huge writedown of goodwill assets a year ago.

Globe and Mail Update Published on Friday, Nov. 06, 2009 5:03PM EST M onday, Nov.

The report also includes M&A statistics and recent partnering news updates by date.

We're sorry, but this web site contains enhanced features not supported by the browser version you are currently using.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Shares of the following companies may have unusual moves in Canadian trading . Stock symbols are in parentheses.

On 10/19/09, Angiotech Pharma received notice from the FDA that Bio-Seal is a Class III medical device that requires Pre-Market Approval for marketing clearance by the Agency.

VANCOUVER, Oct. 19 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. today announced that it has received correspondence from the FDA regarding its 510 submission for Bio-Seal, stating that Bio-Seal is a class III device -- ------------------------ Statements contained in this press release that are not based on historical fact, including ...

Shedio Logging of Slippery Rock invested in Kane in 2006 when it purchased the dilapidated Kane Handle plant property for $70,000. But, after losing the battle with local government officials over their bid for a partial property tax exoneration for 2007, the owners wish they had never made the deal.

Last week's top five stocks that were bought by their CEOs were Angiotech Pharmaceuticals Inc, Blount International Inc, Acorn Energy Inc, ENTERPRISE ACQ CP, and R.G. Barry Corp.

President and CEO of Angiotech Pharmaceuticals Inc. William L Hunter buys 49,500 shares of ANPI on 09/29/2009 at an average price of $1.9 a share.

Angiotech Pharmaceuticals, Inc. today announced that its corporate partner, Boston Scientific Corporation , has released comprehensive data from the TAXUS ATLAS clinical program, a series of global, prospective, single-arm trials evaluating the TAXUS LibertA© Paclitaxel-Eluting Stent System in a variety of lesions and patient groups.

Angiotech Pharmaceuticals, Inc. today announced that its corporate partner, Boston Scientific , has reported two-year data from its SYNTAX clinical trial comparing percutaneous coronary intervention using the Taxus Express Paclitaxel-Eluting Coronary Stent System to coronary artery bypass graft surgery.

According to GuruFocus Insider Data , the largest CFO buys during the past week were Angiotech Pharmaceuticals Inc.

According to GuruFocus Insider Data , the largest CFO buys during the past week were Angiotech Pharmaceuticals Inc.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

AVANIR Pharmaceuticals announced that its investigational drug Zenvia met its primary efficacy endpoint in its Phase III trial.